Samsung Bioepis launches first biosimilar in Japan

Samsung Bioepis said Wednesday it has launched autoimmune disease treatment SB17 in partnership with Nipro Corporation, marking the company’s first product launch in Japan and its full-scale entry into the market.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.